1. Fig 1A: PPV only (n = 5)
Staging EUA
Enucleation
Systemic chemotherapy
PPV
iVit Melphalan
Intra-arterial Chemotherapy
Death
Silicon oil removal
Pathology
Last Follow-up
Retinal detachment surgery
Cataract surgery
cT3d/E
cT2b/D
#32
6.1 1 2 3 4 5
3.3
20/60
#99
4.0
cT2b/D
3.0 1 2 3
20/60
?/?
cT2b/D 6
#84
6.6
3.1 1 2 3 4 5
20/200 1 2 3
#42
4.9
3.2 4
cT3d/E
cT2b/D CF
pT1
7 PPV only
Explain #41 why chemo after
Explain #77 why delay to start treatment from november to march; no chemo?? Or elsewhere? Stage B at diagnosis?
7.7 1 2 3 4 5 6 7
#60
cT2a/C
cT2b/D
3.1 CF
pT2b
Fig 1B: PPV followed by systemic chemotherapy (for the enucleated eye)
(n = 2) 3
#77
3.6
3.0 1 2
cT3a/E
cT1b/B
20/40
pT3b 1 4
4.2
#41
3.2
cT2b/E
cT2b/D 2 3
20/100
20/60
pT3b

2. Fig 1C: PPV followed by Intravitreal Melphalan (n = 10)
20/40
#40
4.1 1 2 3
?/E
cT2b/C
3.3 4 2 3
4.3 1
#25
3.4
cT3c/E
cT2b/D
pT1
20/50
#27
cT3c/E
cT2b/D
4.1
3.3 1 2 3
20/50
pT2a
#28
cT2a/D
cT3c/E
3.3 1 2 3
4.0
20/50 4
#74
cT2b/E
cT2b/D
4.3 1 2 3
3.0
20/60
pT1
9 PPV + IVitC
#26 1
3.3
cT3c/E
cT2b/D
3.6 2
pT2a 3
20/80
cT2b/D
#34
cT2a/C
9.8 1 2 3 4 5 6 7 8 9
3.3
pT2a
20/100
#108
cT2b/E
cT2b/D
4.8 4 2 3 1
2.9 CF
pT1
#37
2.8 1 2
cT2b/E
cT2b/D
2.3 LP
5.3 1 2 4
#29 5
?/? 3
cT2b/D
3.3 LP

3. Fig 1D: Failure, PPV followed by enucleation (2), or repeat PPV (2) with 1 lost to follow-up (n = 4)3 4
#24
cT3c/E
cT2b/D
3.3
NLP
4.3
pT1
#44
cT2b/D
5.4 1 2 3 4 5
1.9
NLP
pT2a
#94
3.0 (2.0)
cT2b/E
cT2b/D
5.8 1 2 3 4 5
20/100
pT2a
#65
cT3b/E
cT2b/D 1 2 3
1.6
3.4 (LTF) ?
pT2a
5 failures after PPV
#94 recurrence one year later; repeat PPV
#29 repair retinal detachment
#37 also retinal detachmnet

4. Included (n = 21) Bilateral, Last Eye
Enucleated (n = 2, 10% )
Eye Assessable (n = 20)
Lost to Follow-up (LTF) (n = 1)
Metastasis / Death (n = 0)
Vision
Not blind (n = 12, 67%)
>20/80 (n = 10)
20/100 to 20/200 (n = 2)
Functional (n = 5, 28%)
Light perception (n = 1, 6%)
Post PPV Rx
None (n = 5)
CEV for other eye high risk path (n = 2)
IVitC, x 1-4 (n = 10)
Repeat PPV (n = 1)
Saved (n = 18, 90% )